216 related articles for article (PubMed ID: 20572362)
1. [Emerging treatments for multiple sclerosis].
Nau JY
Rev Med Suisse; 2010 Jun; 6(251):1162-3. PubMed ID: 20572362
[No Abstract] [Full Text] [Related]
2. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs].
Hecht B
Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402
[TBL] [Abstract][Full Text] [Related]
3. New drugs may improve, complicate treatment for multiple sclerosis.
Link H; Martin R
Nat Med; 2010 Mar; 16(3):272. PubMed ID: 20208513
[No Abstract] [Full Text] [Related]
4. New oral drugs for multiple sclerosis.
Gasperini C; Ruggieri S
Neurol Sci; 2009 Oct; 30 Suppl 2():S179-83. PubMed ID: 19882371
[TBL] [Abstract][Full Text] [Related]
5. Oral therapy for multiple sclerosis--sea change or incremental step?
Carroll WM
N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
[No Abstract] [Full Text] [Related]
6. Oral cladribine and fingolimod for relapsing multiple sclerosis.
Mann H
N Engl J Med; 2010 May; 362(18):1738; author reply 1739-40. PubMed ID: 20445188
[No Abstract] [Full Text] [Related]
7. Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.
Hohlfeld R
Nat Rev Neurol; 2011 Jul; 7(8):425-7. PubMed ID: 21750524
[No Abstract] [Full Text] [Related]
8. Multiple sclerosis poses tough drug development challenges.
Senior K
Drug Discov Today; 2005 Dec; 10(23-24):1583-4. PubMed ID: 16376813
[No Abstract] [Full Text] [Related]
9. [Multiple sclerosis, the therapeutic arsenal of today and tomorrow].
Zéphir H
Soins; 2009 Nov; (740):39-41. PubMed ID: 20014532
[No Abstract] [Full Text] [Related]
10. Fingolimod for multiple sclerosis.
Pelletier D; Hafler DA
N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823
[No Abstract] [Full Text] [Related]
11. [New, effective immunomodulatory drug in treatment of multiple sclerosis: the fingolimod].
Komoly S
Ideggyogy Sz; 2012 Nov; 65(11-12):421-2. PubMed ID: 23289178
[No Abstract] [Full Text] [Related]
12. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
Weissert R
Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
[No Abstract] [Full Text] [Related]
13. [New disease-modifying and symptomatic therapies for multiple sclerosis].
Weise G; Buttmann M
MMW Fortschr Med; 2012 Apr; 154(7):64-6. PubMed ID: 22558878
[No Abstract] [Full Text] [Related]
14. Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
Filippi M
Nat Rev Neurol; 2011 Feb; 7(2):74-5. PubMed ID: 21297650
[No Abstract] [Full Text] [Related]
15. Emerging oral agents for multiple sclerosis.
Fox EJ
Am J Manag Care; 2010 Sep; 16(8 Suppl):S219-26. PubMed ID: 20873946
[TBL] [Abstract][Full Text] [Related]
16. Emerging disease-modifying oral therapies for multiple sclerosis.
Losy J; Kalinowska-Łyszczarz A
J Neuroimmunol; 2011 Feb; 231(1-2):15-22. PubMed ID: 20947176
[TBL] [Abstract][Full Text] [Related]
17. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration.
Massberg S; von Andrian UH
N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715
[No Abstract] [Full Text] [Related]
18. Fingolimod: cardiovascular deaths.
Prescrire Int; 2012 Apr; 21(126):99. PubMed ID: 22515137
[No Abstract] [Full Text] [Related]
19. Update on emerging therapies for multiple sclerosis.
Yiu EM; Banwell B
Expert Rev Neurother; 2010 Aug; 10(8):1259-62. PubMed ID: 20662750
[TBL] [Abstract][Full Text] [Related]
20. [Fingolimod - a new immunomodulator].
Friedrich FW; Eschenhagen T
Dtsch Med Wochenschr; 2009 Oct; 134(42):2127-31. PubMed ID: 19809964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
